tetano
Editor, Senior Moderator
Ann Med Surg (Lond)
. 2022 Jan;73:103194.
doi: 10.1016/j.amsu.2021.103194. Epub 2021 Dec 21.
Covid-19 responsible for acute limb ischemia twice at 2 different stages in a patient on anticoagulation: A case report
Youssef Banana[SUP] 1 [/SUP], Ouahiba Hafhaf[SUP] 1 [/SUP], Sara Boukabous[SUP] 1 [/SUP], Hammam Rasras[SUP] 2 [/SUP], Zakariae Bazid[SUP] 2 3 [/SUP], Noha El Ouafi[SUP] 2 3 [/SUP], Abdellah Rezziki[SUP] 1 3 [/SUP], Adnane Benzirar[SUP] 1 3 [/SUP], Omar El Mahi[SUP] 1 3 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease-2019 is a worldwilde pandemic not limited to pulmonary dysfunction. it is a systemic infection responsible for serious coagulopathies.
Case presentation: We report the case of a patient who presented an acute ischemia of the left lower limb, after day 5 of (Covid-19) infection, with a second thrombotic localization in the left upper limb at the twentieth day of post covid while he was on anticoagulation.
Clinical discussion: Several studies have shown the involvement of the inflammatory process in the thrombotic state in patients with (Covid-19) infection. The inflammatory process leads to the activation of the thrombotic cascade. Various elevated markers have been identified frequently and described to determine the progression of sepsis-induced prothrombotic disease secondary to Covid-19. Our case remains unique in its kind, since the patient presented twice the acute ischemia of the limbs, the first at the left lower limb, while he was on preventive low molecular weight heparin (LMWH), the second time at the left upper limb, while he was on anticoagulation (RIVAROXABAN 20 mg/jr). Although the efficiency of preventive anticoagulation in Covid-19 patients has not been established, it remains systematic as a prescription in the hospital environment.
Conclusion: All in all, The regular monitoring of vascular markers thrombosis, and preventive anticoagulation remains the only weapon available to any clinician to fight against vascular thrombotic complications in Covid-19 patients, though its realiability has not been proven.
Keywords: Coagulopathies; Covid-19; Inflammatory; Preventive anticoagulation.
. 2022 Jan;73:103194.
doi: 10.1016/j.amsu.2021.103194. Epub 2021 Dec 21.
Covid-19 responsible for acute limb ischemia twice at 2 different stages in a patient on anticoagulation: A case report
Youssef Banana[SUP] 1 [/SUP], Ouahiba Hafhaf[SUP] 1 [/SUP], Sara Boukabous[SUP] 1 [/SUP], Hammam Rasras[SUP] 2 [/SUP], Zakariae Bazid[SUP] 2 3 [/SUP], Noha El Ouafi[SUP] 2 3 [/SUP], Abdellah Rezziki[SUP] 1 3 [/SUP], Adnane Benzirar[SUP] 1 3 [/SUP], Omar El Mahi[SUP] 1 3 [/SUP]
Affiliations
- PMID: 34956641
- PMCID: PMC8693672
- DOI: 10.1016/j.amsu.2021.103194
Abstract
Introduction: Coronavirus disease-2019 is a worldwilde pandemic not limited to pulmonary dysfunction. it is a systemic infection responsible for serious coagulopathies.
Case presentation: We report the case of a patient who presented an acute ischemia of the left lower limb, after day 5 of (Covid-19) infection, with a second thrombotic localization in the left upper limb at the twentieth day of post covid while he was on anticoagulation.
Clinical discussion: Several studies have shown the involvement of the inflammatory process in the thrombotic state in patients with (Covid-19) infection. The inflammatory process leads to the activation of the thrombotic cascade. Various elevated markers have been identified frequently and described to determine the progression of sepsis-induced prothrombotic disease secondary to Covid-19. Our case remains unique in its kind, since the patient presented twice the acute ischemia of the limbs, the first at the left lower limb, while he was on preventive low molecular weight heparin (LMWH), the second time at the left upper limb, while he was on anticoagulation (RIVAROXABAN 20 mg/jr). Although the efficiency of preventive anticoagulation in Covid-19 patients has not been established, it remains systematic as a prescription in the hospital environment.
Conclusion: All in all, The regular monitoring of vascular markers thrombosis, and preventive anticoagulation remains the only weapon available to any clinician to fight against vascular thrombotic complications in Covid-19 patients, though its realiability has not been proven.
Keywords: Coagulopathies; Covid-19; Inflammatory; Preventive anticoagulation.